Biotronik's rate-adaptive pacemakers get US clearance:
This article was originally published in Clinica
Executive Summary
Biotronik has obtained FDA approval to launch its Actros family of rate-adaptive single and dual chamber pacemakers. The 6mm wide device can switch modes within one cycle to correct atrial arrhythmia, and uses 50% less power than earlier devices, says the company.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.